Morepen Laboratories Share Price Today (MOREPENLAB)
TODAY IN ONE LINE
MOREPENLAB fell 2.4% on light volume, lagging Nifty's -0.0% move.
With a market cap of ₹3,035.12 Cr., it trades at a P/E of 31.96. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Morepen Laboratories flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 18.9% YoY
- ●Poor Capital ReturnsLow ROE of 6.2%
- ●Rising Receivables vs SalesReceivables grew 11.4% outpacing sales growth of 7.2%
Latest Morepen Laboratories News
What changed recently?
Recent events, corporate actions, and announcements.
Morepen Laboratories Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Morepen Laboratories Limited, framed against the sector median so the premium or discount is obvious at a glance.
Morepen Laboratories Limited trades at a P/E of 31.96× and P/B of 2.43×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Morepen Laboratories Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Morepen Laboratories Limited — derived from the live tape, not yesterday's close.
Morepen Laboratories Limited last traded at ₹55.3 with an intraday range of ₹55.01–₹56.89 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹55.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 60.22 | +4.92 | +8.89% |
| R3 | 58.34 | +3.04 | +5.49% |
| R2 | 57.61 | +2.31 | +4.18% |
| R1 | 56.46 | +1.16 | +2.09% |
| PIVOT | 55.73 | 0.43 | 0.78% |
| CURRENT | 55.30 | — | — |
| S1 | 54.58 | -0.72 | -1.31% |
| S2 | 53.85 | -1.45 | -2.62% |
| S3 | 52.70 | -2.60 | -4.71% |
| S4 | 50.82 | -4.48 | -8.11% |
MOREPENLAB is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹56.11–₹56.89
Trading Inside opening range
Morepen Laboratories Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Morepen Laboratories Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Morepen Laboratories Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹3,035.12 Cr. and reported EPS of ₹1.79.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,812 | 1,806 ▼ 0.3% |
| Sales Growth YoY %Derived | 7.17% | -0.32% |
| Other Income | 18 | 21 ▲ 16.1% |
| Total Income | 1,830 | 1,827 ▼ 0.2% |
| 1,159 | 1,123 ▼ 3.1% | |
| Gross ProfitDerived | 652 | 682 ▲ 4.6% |
| Gross Margin %Derived | 36.01% | 37.78% |
| 478 | 557 ▲ 16.4% | |
| EBITDA (Operating Profit)Derived | 174 | 126 ▼ 27.8% |
| OPM %Derived | 9.61% | 6.96% |
| 37 | 79 ▲ 110.8% | |
| Profit Before Tax (PBT) | 155 | 120 ▼ 22.7% |
| 37 | 24 ▼ 34.6% | |
| Effective Tax %Derived | 23.91% | 20.24% |
| Total Profit for Period | 118 | 95 ▼ 19.6% |
| Net Profit (Owner's PAT)Derived | 118 | 95 ▼ 19.6% |
| Net Profit Margin %Derived | 6.51% | 5.25% |
| PAT Growth YoY %Derived | 22.73% | -19.61% |
| Earnings Per Share (EPS ₹) | 2.15 | 1.73 ▼ 19.5% |
| Diluted Shares Outstanding (Cr) | 55 | 55 ▲ 0.0% |
| Share of Profit from Associates/JVs | 0 | -1 ▼ 15494.0% |
| Other Comprehensive Income (Net of Tax) | 0 | 6 ▲ 2339.5% |
| Total Expenses (incl. D&A & Interest) | 1,675 | 1,707 ▲ 1.9% |
| Material Cost % of RevenueDerived | 55.16% | 57.77% |
| Employee Cost % of RevenueDerived | 11.53% | 12.89% |
| Other Cost % of RevenueDerived | 14.86% | 17.94% |
| Interest Coverage (x)Derived | 17.39x | 5.43x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 607 | 769 ▲ 26.7% | 853 ▲ 11.0% | 1,188 ▲ 39.3% | 1,547 ▲ 30.2% | 1,418 ▼ 8.4% | 1,690 ▲ 19.3% | 1,812 ▲ 7.2% | 1,806 ▼ 0.3% | |
| Sales Growth YoY %Derived | — | 26.72% | 11.00% | 39.27% | 30.20% | -8.36% | 19.25% | 7.17% | -0.32% | |
| Other Income | 4 | 4 ▼ 1.4% | 9 ▲ 158.3% | 12 ▲ 27.3% | 10 ▼ 14.6% | 6 ▼ 40.5% | 14 ▲ 127.8% | 18 ▲ 31.4% | 21 ▲ 16.1% | |
| Total Income | 610 | 772 ▲ 26.5% | 863 ▲ 11.7% | 1,200 ▲ 39.1% | 1,557 ▲ 29.7% | 1,424 ▼ 8.6% | 1,704 ▲ 19.7% | 1,830 ▲ 7.4% | 1,827 ▼ 0.2% | |
369 | 496 ▲ 34.7% | 557 ▲ 12.3% | 781 ▲ 40.0% | 1,049 ▲ 34.4% | 956 ▼ 8.9% | 1,062 ▲ 11.2% | 1,159 ▲ 9.1% | 1,123 ▼ 3.1% | ||
| Gross ProfitDerived | 238 | 272 ▲ 14.3% | 296 ▲ 8.7% | 408 ▲ 37.8% | 498 ▲ 22.1% | 462 ▼ 7.2% | 628 ▲ 36.0% | 652 ▲ 3.9% | 682 ▲ 4.6% | |
| Gross Margin %Derived | 39.23% | 35.40% | 34.66% | 34.30% | 32.16% | 32.58% | 37.15% | 36.01% | 37.78% | |
173 | 205 ▲ 18.1% | 227 ▲ 11.1% | 289 ▲ 27.2% | 361 ▲ 24.9% | 382 ▲ 5.9% | 469 ▲ 22.8% | 478 ▲ 1.9% | 557 ▲ 16.4% | ||
| EBITDA (Operating Profit)Derived | 65 | 68 ▲ 4.3% | 69 ▲ 1.5% | 119 ▲ 73.0% | 137 ▲ 15.3% | 80 ▼ 41.8% | 159 ▲ 99.4% | 174 ▲ 9.7% | 126 ▼ 27.8% | |
| OPM %Derived | 10.67% | 8.79% | 8.03% | 9.98% | 8.84% | 5.61% | 9.38% | 9.61% | 6.96% | |
39 | 42 ▲ 8.6% | 39 ▼ 7.4% | 32 ▼ 17.5% | 20 ▼ 36.8% | 30 ▲ 47.5% | 37 ▲ 24.3% | 37 ▲ 0.4% | 79 ▲ 110.8% | ||
| Profit Before Tax (PBT) | 30 | 29 ▼ 2.0% | 39 ▲ 34.0% | 99 ▲ 151.9% | 127 ▲ 28.6% | 56 ▼ 56.0% | 135 ▲ 142.9% | 155 ▲ 14.5% | 120 ▼ 22.7% | |
— | 0 | 6 ▲ 1544.0% | 1 ▼ 74.3% | 25 ▲ 1660.2% | 17 ▼ 31.7% | 39 ▲ 127.1% | 37 ▼ 4.4% | 24 ▼ 34.6% | ||
| Effective Tax %Derived | — | 1.15% | 14.14% | 1.44% | 19.75% | 30.63% | 28.65% | 23.91% | 20.24% | |
| Total Profit for Period | 30 | 29 ▼ 2.5% | 34 ▲ 16.4% | 97 ▲ 189.1% | 102 ▲ 4.7% | 39 ▼ 62.0% | 96 ▲ 148.6% | 118 ▲ 22.7% | 95 ▼ 19.6% | |
| Net Profit (Owner's PAT)Derived | 30 | 29 ▼ 2.5% | 34 ▲ 16.4% | 97 ▲ 189.1% | 102 ▲ 4.7% | 39 ▼ 62.0% | 96 ▲ 148.6% | 118 ▲ 22.7% | 95 ▼ 19.6% | |
| Net Profit Margin %Derived | 4.88% | 3.75% | 3.94% | 8.17% | 6.57% | 2.73% | 5.69% | 6.51% | 5.25% | |
| PAT Growth YoY %Derived | — | -2.51% | 16.40% | 189.13% | 4.73% | -61.96% | 148.63% | 22.73% | -19.61% | |
| Earnings Per Share (EPS ₹) | 0.66 | 0.64 ▼ 3.0% | 0.75 ▲ 17.2% | 2.16 ▲ 188.0% | 2.13 ▼ 1.4% | 0.76 ▼ 64.3% | 1.88 ▲ 147.4% | 2.15 ▲ 14.4% | 1.73 ▼ 19.5% | |
| Diluted Shares Outstanding (Cr) | 45 | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 48 ▲ 6.2% | 51 ▲ 7.0% | 51 ▲ 0.0% | 55 ▲ 7.2% | 55 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -0 | 0 ▲ 105.0% | 0 ▼ 96.6% | -0 ▼ 1466.7% | 0 ▲ 134.1% | -0 ▼ 121.4% | -0 ▼ 153366.7% | 0 ▲ 101.1% | -1 ▼ 15494.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -2 ▼ 2014.4% | -3 ▼ 53.8% | -0 ▲ 94.4% | -0 ▼ 152.0% | -1 ▼ 299.0% | -2 ▼ 24.4% | 0 ▲ 113.8% | 6 ▲ 2339.5% | |
| Total Expenses (incl. D&A & Interest) | 580 | 743 ▲ 28.0% | 823 ▲ 10.8% | 1,102 ▲ 33.8% | 1,430 ▲ 29.8% | 1,368 ▼ 4.4% | 1,569 ▲ 14.7% | 1,675 ▲ 6.7% | 1,707 ▲ 1.9% | |
| Material Cost % of RevenueDerived | 36.36% | 44.64% | 48.44% | 52.01% | 51.53% | 55.12% | 52.25% | 55.16% | 57.77% | |
| Employee Cost % of RevenueDerived | 12.62% | 12.41% | 12.88% | 11.41% | 10.62% | 10.91% | 10.73% | 11.53% | 12.89% | |
| Other Cost % of RevenueDerived | 15.94% | 14.20% | 13.74% | 12.91% | 12.71% | 16.05% | 17.03% | 14.86% | 17.94% | |
| Interest Coverage (x)Derived | 6.98x | 13.09x | 15.93x | 49.34x | -14.80x | 26.05x | 33.73x | 17.39x | 5.43x |
Morepen Laboratories segment analysis : revenue and profit mix.
Disclosed business segments at Morepen Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Morepen Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Morepen Laboratories Limited.
Our AI distills the core fundamental drivers supporting Morepen Laboratories Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Morepen Laboratories Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Ultra-low debt-to-equity ratio of 0.17x ensures strong financial stability and flexibility.
Positive operating cash flow of ₹20.47 Cr in FY26 signals operational liquidity generation.
Diversified product portfolio across APIs, OTC, and home healthcare reduces revenue concentration risk.
Promoter holding of 35.65% provides stable governance and long-term strategic alignment.
Book value per share of ₹22.17 supports tangible asset backing for equity investors.
Key Risks.
Latest quarterly EPS declined 22.5% YoY, signaling severe earnings volatility and investor concern.
TTM EPS declined 18.9% YoY despite flat revenue growth, indicating margin compression.
Operating margin of 4.94% significantly lags peer median of 10–15%, limiting pricing power.
ROE of 6.20% and ROA of 4.04% substantially underperform peer benchmarks of 12–16%.
Negative free cash flow of ₹98.55 Cr in FY26 raises capital deployment efficiency concerns.
Flip Conditions.
Valuation risk. a P/E above 42 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Morepen Laboratories Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Morepen Laboratories Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Morepen Laboratories Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Morepen Laboratories Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Morepen Laboratories Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Morepen Laboratories Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Morepen Laboratories Limited stood at 40.5% of traded volume, against a 20-day average of 32.7%.
Morepen Laboratories announcements: results, concalls, ratings, M&A.
Filings Morepen Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Morepen Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 70 documents below.
General Updates
MOREPENLAB: Morepen Laboratories Limited has informed the Exchange about Name Change Of Wholly Owned Subsidiary Company from "Morepen Labs - FZCO" to…
Resignation of Director/KMP/SMP
Morepen Laboratories Limited has informed the Exchange about Resignation of Director/KMP/SMP
Resignation
Morepen Laboratories Limited has informed the Exchange regarding resignation of Mr. Bhola Prasad as General Manager Process Engineering &…
Press Release
Morepen Laboratories Limited has informed the Exchange regarding a press release dated July 01, 2026, titled Morepen starts commercial supplies…
Change in Management
Morepen Laboratories Limited has informed the Exchange about elevation and change in designation of Mr. Sanjay Suri
Investor decks & rating reports.
Morepen Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Morepen Laboratories has declared, sequenced by announce and record date.
Morepen Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Morepen Laboratories Limited: business, sector, key facts.
What Morepen Laboratories Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Morepen Laboratories Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: MOREPENLAB, BSE: 500288.
Morepen Laboratories Limited is a multinational company headquartered in Gurugram, India, established in 1984. Their core business revolves around the development, manufacturing, marketing, and sale of a diverse range of healthcare products across several key sectors. This includes a significant presence in the Active Pharmaceutical Ingredients (API) market, providing crucial components for various medications.
A substantial portion of Morepen's business focuses on the production and distribution of APIs. These APIs are used in the creation of pharmaceuticals targeting a wide spectrum of conditions, including allergies (anti-histaminic, anti-asthmatic), cardiovascular issues (anti-lipemic, anti-hypertensive, anti-coagulant), diabetes (anti-diabetic), ulcers (anti-ulcerative), and mental health (anti-depressant). This underscores their significant role in the pharmaceutical supply chain.
Beyond APIs, Morepen Laboratories also manufactures and sells a broad range of home healthcare products. This segment encompasses a considerable selection of diagnostic tools and equipment, such as blood glucose monitors and test strips, blood pressure monitors (sphygmomanometers), digital thermometers, nebulizers, pulse oximeters, and even air purifiers. This comprehensive array of products caters to both professional and personal healthcare needs.
Furthermore, Morepen offers a diverse portfolio of Over-The-Counter (OTC) and healthcare products marketed under the prominent "Dr. Morepen" brand. This includes a wide array of medications and remedies designed to address common ailments like fever, pain, constipation, and acidity. The brand also extends to products focused on specific health areas, encompassing formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, allergy treatment, central nervous system disorders, cardiology, diabetology, and nutraceuticals. This demonstrates a strategic approach to capturing a broad market share across various healthcare segments.
In summary, Morepen Laboratories' business model is multifaceted and encompasses a vertically integrated approach from the production of APIs to the development and marketing of finished pharmaceutical products and home healthcare devices. Their geographical reach extends internationally, with a focus on India and the United States, demonstrating a considerable level of market penetration and a robust business strategy.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Morepen Laboratories Limited (MOREPENLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Morepen Laboratories Limited (MOREPENLAB)?
The current share price of Morepen Laboratories Limited (MOREPENLAB) is ₹55.3. Today, the stock has declined by ₹1.36 (2.40%), trading in a range of ₹55.01 to ₹56.89. The stock opened at ₹56.55 with a trading volume of 30,92,284 shares.
02Is Morepen Laboratories Limited stock a good investment for long-term?
Morepen Laboratories Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,035.12 crores, P/E ratio of 31.96, ROE of 6.20%, and ROCE of 8.05%. The dividend yield stands at 0.33%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Morepen Laboratories Limited stock?
The 52-week high price of Morepen Laboratories Limited (MOREPENLAB) is ₹64.58, while the 52-week low is ₹33.05. Currently trading at ₹55.3, the stock is 70.6% away from its 52-week low and 14.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Morepen Laboratories Limited stock at the current price?
Whether to buy Morepen Laboratories Limited stock at ₹55.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 31.96 and P/B ratio of 2.43. Today's performance shows a loss of 2.40%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Morepen Laboratories Limited and when is the next dividend?
Morepen Laboratories Limited offers a dividend yield of 0.33%, which means for every ₹100 invested at the current price of ₹55.3, you can expect to receive approximately ₹0.33 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Morepen Laboratories Limited?
Morepen Laboratories Limited's key financial metrics include: P/E Ratio: 31.96, P/B Ratio: 2.43, ROE: 6.20%, ROCE: 8.05%, Dividend Yield: 0.33%, EPS: ₹1.79, Book Value: ₹22.17, and Debt-to-Equity: 0.17. The company's market cap stands at ₹3,035.12 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Morepen Laboratories Limited stock performing today in the market?
Morepen Laboratories Limited stock opened at ₹56.55 and is currently trading at ₹55.3, showing a decline of ₹1.36 (2.40%). The intraday high is ₹56.89 and low is ₹55.01. The trading volume stands at 30,92,284 shares, indicating strong market participation today.
08What is the P/E ratio of Morepen Laboratories Limited and what does it indicate?
Morepen Laboratories Limited has a Price-to-Earnings (P/E) ratio of 31.96, which means investors are willing to pay ₹31.96 for every ₹1 of earnings. With an EPS of ₹1.79, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Morepen Laboratories Limited (MOREPENLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.